FDA OK for Gaucher drug opens new market for Pfizer, Protalix

After initially being rebuffed at the FDA Pfizer ($PFE) and Protalix have snagged an FDA OK for their new Gaucher disease drug Elelyso (taliglucerase), an orphan enzyme replacement therapy which will…
Read the full story: News